Oramed Pharmaceuticals Inc.

The momentum for this stock is not very good. Oramed Pharmaceuticals Inc. is not very popular among insiders. Oramed Pharmaceuticals Inc. is a mediocre stock to choose.
Log in to see more information.
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered...
ORMP Fundamental Data by TradingView

News

Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Lowered to Hold at StockNews.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Lowered to Hold at StockNews.com

Zolmax Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) was downgraded by StockNews.com from a "buy" rating to a "hold" rating in a note issued to investors on Tuesday.\nSeparately, HC Wainwright...\n more…

Oramed Pharmaceuticals (NASDAQ:ORMP) Lowered to "Hold" at StockNews.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Lowered to "Hold" at StockNews.com

Ticker Report Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) was downgraded by equities researchers at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Tuesday. Separately...\n more…

Q3 2024 EPS Estimates for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Lifted by HC Wainwright
Q3 2024 EPS Estimates for Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) Lifted by HC Wainwright

Ticker Report Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - HC Wainwright upped their Q3 2024 earnings estimates for Oramed Pharmaceuticals in a research note issued to investors on Monday, September...\n more…

Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Reiterated by HC Wainwright
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Reiterated by HC Wainwright

Zolmax Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report)s stock had its "neutral" rating reaffirmed by equities research analysts at HC Wainwright in a report issued on Monday, Benzinga...\n more…

Brokers Offer Predictions for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP)
Brokers Offer Predictions for Oramed Pharmaceuticals Inc.'s Q3 2024 Earnings (NASDAQ:ORMP)

Zolmax Oramed Pharmaceuticals Inc. (NASDAQ:ORMP - Free Report) - Investment analysts at Zacks Small Cap cut their Q3 2024 earnings per share estimates for Oramed Pharmaceuticals in a research report...\n more…

Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Buy at StockNews.com
Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Buy at StockNews.com

Zolmax Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating in a research report issued on Tuesday.\nSeparately, HC...\n more…